Spots Global Cancer Trial Database for A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies
Official Title: A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies
Study ID: NCT02954445
Interventions
Study Description
Brief Summary: The overall purpose of this study is to explore the therapeutic effect of BCMA-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of B-cell derived malignancies.
Detailed Description: B-cell maturation antigen(BCMA) is preferentially expressed in mature B lymphocytes as well as in B-cell derived leukemia, lymphomas, and multiple myeloma. Despite of the fact that CD19-targeted CAR-T can re-induce remissions for many patients with relapsed and refractory B cell malignancies, a part of those patients will relapse with CD19-negative malignancies. To explore a rescue for those with CD19-negative B cell malignancies, this trial is designed and conducted to test the safety and effect of BCMA-targeted CAR-T.
Eligibility
Minimum Age: 14 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Southwest Hospital of Third Millitary Medical University, Chongqing, Chongqing, China
Contact Details
Name: Cheng Qian, MD, PhD
Affiliation: Biotherapy Center of Southwest Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
